

Strongyloides IgG ELISA Kit

Strongy-G-96

Intended Use

The *Strongyloides* ELISA test is a qualitative enzyme immunoassay for the detection of antibodies to *Strongyloides*, in samples of human serum or plasma. This test is intended to be performed by trained medical technologists only.

Summary and Explanation

Strongyloidiasis is the disease caused by the *Strongyloides stercoralis* parasite. This organism is an intestinal nematode with worldwide distribution, but is especially common in tropical and subtropical regions. The disease usually manifests as intestinal symptoms (mild diarrhea). In a minority of cases, the organism will become extra-intestinal and may lead to septic shock and meningitis. Serological tests are useful in detecting infection by *Strongyloides* if the organism goes extra-intestinal and in excluding the organism from the diagnosis of other disorders (especially hematologic malignancies). *Strongyloides* infected patients are particularly at risk for severe complications if they are also immunocompromised.

Assay Principle

The microwells are coated with *Strongyloides* L3 antigen. During the first incubation with the diluted patients' sera, any antibodies which are reactive with the antigen will bind to the coated wells. After washing to remove the rest of the sample, the Enzyme Conjugate is added. If antibodies have been bound to the wells, the Enzyme Conjugate will then bind to these antibodies. After another series of washes, a chromogen (tetramethylbenzidine or TMB) is added. If the Enzyme Conjugate is present, the peroxidase will catalyze a reaction that consumes the peroxide and turns the chromogen from clear to blue. Addition of the Stop Solution ends the reaction and turns the blue color to a bright yellow color. The reaction may then be read visually or with an ELISA reader.

Reagents

Item	Description	Symbol
Test Strips	Microwells containing <i>Strongyloides</i> L3 antigens - 96 test wells in a test strip holder.	MT PLATE
Enzyme Conjugate	One (1) bottle containing 11 ml of Protein-A conjugated to peroxidase.	CONJ
Positive Control	One (1) vial containing 2 ml of a surrogate positive control.	CONTROL +
Negative Control	One (1) vial containing 2 ml of diluted human sera.	CONTROL -
Chromogen	One (1) bottle containing 11 ml of the chromogen tetramethylbenzidine (TMB).	SUBS TMB
Wash Concentrate (20X)	Two (2) bottles containing 25 ml of concentrated buffer and surfactant.	WASH BUF
Dilution Buffer	Two (2) bottles containing 30 ml of buffered protein solution.	SPECM DIL
Stop Solution	One (1) bottle containing 11 ml of 1 M phosphoric acid.	SOLN

Statement of Warnings

- **Do not deviate from the specified procedures when performing this assay.** All specimen dilutions, incubation times/temperatures and washings have been optimized for the best performance characteristics. Deviations from the specified procedures may affect the sensitivity and specificity of the assay.
- For In Vitro Diagnostic Use Only.
- Do not interchange reagents between kits with different lot numbers.
- Do not use reagents that are beyond their expiration dates. Expiration dates are on each reagent label. Use of reagents beyond their expiration dates may affect results.
- Unused microwells should be stored in the desiccated pouch to protect them from moisture.
- Do not use solutions if they precipitate or become cloudy.
Exception: Wash concentrate may precipitate during refrigerated storage, but will dissolve upon warming.
- Do not add azides to the samples or any of the reagents.
- Controls and some reagents contain Thimerosal as a preservative, which may be irritating to skin, eyes and mucous membranes. In case of contact, flush eyes or rinse skin with copious amounts of water.
- Do not use serum that may have supported microbial growth, or is cloudy due to high lipid content. Samples high in lipids should be clarified before use.
- Treat all reagents and samples as potentially infectious materials. Positive control has been tested and found negative for Hepatitis B surface antigen and for the antibody to HIV by required test methods. Use care to prevent aerosols and decontaminate any spills of samples.
- Stop solution is a 5% solution of phosphoric acid in water. If spilled on the skin, wash with copious amounts of water. If acid gets into the eyes, wash with copious amounts of water and seek medical attention.

Storage

- Reagents, strips and bottled components should be stored at 2-8 °C
- Squeeze bottle containing diluted wash buffer may be stored at room temperature (15-25 °C)

Preparation

- Before use, bring all reagents and samples to room temperature (15-25 °C) and mix.
- (20X) Wash Concentrate may precipitate during refrigerated storage, but will go back into solution when brought to room temperature and mixed. **Ensure that (20X) Wash Concentrate is completely in solution before diluting to working concentration.** To dilute (20X) wash concentrate to working dilution, remove cap and add contents of one bottle of Wash Concentrate to a squeeze bottle containing 475 ml of DI water. Swirl to mix. Squeeze bottle should have a narrow tip to optimize washings.

Specimen Collection And Handling

Serum or plasma may be stored at 2-8 °C for up to five days. Sample may be frozen below -20 °C for extended periods. Freezing whole blood samples is not advised. Do not heat inactivate samples and avoid repeated freezing and thawing of samples.

Procedure

Materials Provided

Strongyloides IgG ELISA Kit

Materials Required But Not Provided

- Micropipette
- Squeeze bottle for washing strips (narrow tip is recommended)
- Reagent grade (DI) water
- Graduated Cylinder
- Sample Dilution Tubes
- Absorbent paper

Suggested Materials

ELISA plate reader with a 450 nm and a 620 - 650 nm filter (optional if results are read visually)

Proper Temperature

All incubations are at room temperature (15-25 °C)

Test Procedure

Notes:

- Ensure all samples and reagents are at room temperature (15-25°C)
 - When running the assay, try to avoid the formation of bubbles in the wells. Bubbles may affect overall performance and reading of end results. Slapping the wells out on a clean absorbent towel after each step should help to minimize bubbles in the wells.
 - Negative and positive controls are supplied pre-diluted. DO NOT dilute further.
1. Break off number of wells needed (two for controls plus number of samples) and place in strip holder.
 2. Dilute patient sera 1:64 using the Dilution Buffer (e.g. 5 µl sera and 315 µl dilution buffer).
 3. Add **100 µl** of the negative control to well #1, **100 µl** of the positive control to well #2 and **100 µl** of the diluted test samples to the remaining wells.
 4. Incubate at room temperature for **10 minutes**, then wash.* After last wash step, slap the wells on a clean absorbent towel to remove excess wash buffer.
 5. Add **100 µl** of Enzyme Conjugate to each well.
 6. Incubate at room temperature for **5 minutes**, then wash.* After last wash step, slap the wells on a clean absorbent towel to remove excess wash buffer.
 7. Add **100 µl** of the Chromogen to each well.
 8. Incubate at room temperature for **5 minutes**.
 9. Add **100 µl** of the Stop Solution to each well. Mix wells by gently tapping the side of the strip holder with index finger for approximately **15 seconds**.
 10. Read within one hour of adding Stop Solution.

*** Washings consist of vigorously filling each well to overflowing and decanting contents three (3) separate times. If using automated washers; add 1 minute dwell time between washings and increase number of washes from three to five.**

For Automated Use: Decrease run times to 7-4-3 minute steps.

Reading Results

Visually: Look at each well against a white background (e.g. paper towel) and record as clear or +, ++ or +++ reaction.

ELISA Reader: Zero reader on air. Set for bichromatic readings at 450/620-650 nm.

Quality Control

The use of controls allows validation of kit stability. The kit should not be used if any of the controls are out of range.

Expected values for the controls are:

Negative - 0.0 to 0.2 OD units

Positive - 0.5 OD units and above

Troubleshooting

Negative control has excessive color after development.

Reason: inadequate washings

Correction: wash more vigorously. Remove excessive liquid from the wells by tapping against an Absorbent towel. Do not allow test wells to dry out.

Interpretation of the Test – ELISA Reader

Zero ELISA reader on air. Read all wells at 450/650-620 nm.

Positive – Absorbance reading equal to or greater than 0.2 OD units.

Negative - Absorbance reading less than 0.2 OD units

Limitations of The Procedure

Diagnosis of *Strongyloides* infection should not be made solely based on results of the ELISA *Strongyloides* test alone, but in conjunction with other clinical signs and symptoms and other laboratory findings. Epidemiologic factors, clinical findings, exposure to endemic regions, and other laboratory results should be considered when making a diagnosis.

Expected Values

The number of antibody positive subjects in a population depends on two factors: disease prevalence and clinical criteria used to select the tested population. Because very few positives should be seen in a randomly screened population in a non-endemic area, most serology tests are not specific enough to screen non-endemic populations. Even in an endemic region, serology screening often yields many false positives if used to randomly screen patients. Serology tests are useful to test patients in an endemic region with signs and symptoms consistent with the disease.

Performance Characteristics

		Reference Method*	
		+	-
NLD LLC	+	12	0
	-	0	34

Positive Agreement: 100% (12/12)

Negative Agreement: 100% (34/34)

*Reference Method refers to a commercially available ELISA.

References

1. Schaffel, R. et. al. The Value of An Immunoenzymatic Test for the Diagnosis of Strongyloidiasis in Patients Immunosuppressed by Hematologic Malignancies. A, J Trop Med Hyg. #65(4) 2001. pp. 346-350.
2. Libman, M. et. al. Screening for Schistosomiasis, Filariasis and Strongyloidiasis Among Expatriates Returning from the Tropics. Clin Infect Dis. #17, 1993 pp.353-359
3. Loutfy, M. et. al.. Serology and Eosinophil Count in the Diagnosis and Management of Strongyloides in a Non-endemic Area. Am J Trop Med Hyg. #66(6). 2002 pp.749-752
4. Siddiqui, A. and Berk, S. Diagnosis of Strongyloides stercoralis Infection, CID #33 2001 pp. 1040-1047